Study of NS2359 for ADHD in Adults
Author Information
Author(s): Timothy E Wilens, Thorsten Klint, Lenard Adler, Scott West, Keith Wesnes, Ole Graff, Birgit Mikkelsen
Primary Institution: Massachusetts General Hospital & Harvard Medical School
Hypothesis
The study aimed to investigate the efficacy, safety, and cognitive function of NS2359 in adults with ADHD.
Conclusion
No overall effect of NS2359 was found on ADHD symptoms, but there was a modest improvement in inattentive adults and cognitive function.
Supporting Evidence
- NS2359 showed no significant difference in overall ADHD symptoms compared to placebo.
- In the inattentive subgroup, 41% of patients responded to NS2359 compared to 7% for placebo.
- NS2359 improved cognitive function in attention and episodic memory.
- No serious adverse events were reported during the study.
- Common side effects included insomnia, headaches, and loss of appetite.
Takeaway
The study tested a new medicine for ADHD but found it didn't help most people, though it seemed to help some who had trouble paying attention.
Methodology
The study was a multi-centre, double-blind, randomized placebo-controlled trial testing 0.5 mg NS2359 vs. placebo for 8 weeks.
Potential Biases
The study population was homogenous and may not generalize to typical adults with ADHD.
Limitations
The study had a small sample size and only tested one low dose of NS2359, which may have underestimated its effects.
Participant Demographics
{"age_range":"18-55","gender_distribution":{"male":89,"female":37},"ethnic_distribution":{"caucasian":105,"african_american":7,"asian":3,"other":11}}
Statistical Information
P-Value
p < 0.01
Statistical Significance
p < 0.01
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website